GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » LT-Debt-to-Total-Asset

Embecta (FRA:JX7) LT-Debt-to-Total-Asset : 1.36 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Embecta's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 1.36.

Embecta's long-term debt to total assets ratio increased from Dec. 2023 (1.33) to Dec. 2024 (1.36). It may suggest that Embecta is progressively becoming more dependent on debt to grow their business.


Embecta LT-Debt-to-Total-Asset Historical Data

The historical data trend for Embecta's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta LT-Debt-to-Total-Asset Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - - 1.50 1.34 1.24

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.35 1.28 1.24 1.36

Embecta LT-Debt-to-Total-Asset Calculation

Embecta's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )/Total Assets (A: Sep. 2024 )
=1437.546/1158.055
=1.24

Embecta's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=1494.098/1097.773
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embecta  (FRA:JX7) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Embecta LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Embecta's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Embecta Headlines

No Headlines